India's Ipca Laboratories falls, analysts cut TP after Q4 results

Ipca Laboratories

02/06/2025 09:14

** Shares of Ipca Laboratories IPCA.NS fall 2.8% to 1,384.7 rupees

** Nomura says pharma co's 8-10% FY26 rev growth guidance lower than brokerage's previous estimates, reduces PT by 9.7% to 1,590 rupees, keeps "buy" rating on stock

** HSBC Research cuts PT by 2.9% to 1,330 rupees, maintains "hold"; expects volatility in IPCA's export revenues to outweigh India growth

** HSBC says startup costs for four plants and input cost swings could also weigh on IPCA's margins in near-term

** IPCA reported 13.8% Y/Y rise in Q4 consol net profit; rev up 10.5%

** More than 616,000 shares traded, nearly 3 times the 30-day avg

** Avg rating on stock is "buy;" median PT is 1,615.5 rupees - data compiled by LSEG

** Stock down 18.3% YTD

 (Reporting by Aleef Jahan in Bengaluru)

 ((aleefjahan.cs@thomsonreuters.com))